Definium Therapeutics (DFTX) reported a FY 2025 net loss of USD 183.8 million and a loss from operations of USD 166.3 million, as R&D expenses rose to USD 117.7 million (+80.2%) and G&A expenses increased to USD 48.6 million (+25.9%). Interest income was USD 11.0 million in FY 2025, while interest expense was USD 5.5 million. Cash, cash equivalents and investments totaled USD 411.6 million as of Dec. 31, 2025, and total assets were USD 440.1 million. On the business side, Definium Therapeutics said its Phase 3 MDD trial Emerge is fully enrolled (149 patients) with topline data anticipated in late Q2 2026, while Phase 3 GAD trial Voyage was about 80% enrolled with topline data expected in early Q3 2026 and no enrollment increase required after a blinded sample size re-estimation. The company also said it initiated a Phase 2a open-label study of DT402 (R(-)-MDMA) in adults with autism spectrum disorder in Q4 2025, with initial data anticipated in 2026. Definium Therapeutics completed an equity financing in Q4 2025 raising about USD 259 million in gross proceeds, extending its cash runway into 2028, and announced leadership updates including the appointment of a new CFO and CCO, plus a board addition in January 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260226343522) on February 26, 2026, and is solely responsible for the information contained therein.
Comments